Breast cancer is the second leading cause of death in American women and family history is known to be a significant factor for the development of this disease. BRCA1, the breast cancer susceptibility gene located on chromosome 17 has recently been isolated. Almost simultaneously, chromosome 13q12-13 was identified as the locale of another such gene by genetic linkage analysis. In collaboration with the group responsible for isolation of BRCA1, we plan to further localize and ultimately isolate BRCA2. Our goals include identification additional families with evidence of linkage between breast cancer and genetic markers flanking BRCA2. These families will be studied for informative meiotic recombination events that will narrow the BRCA2 candidate interval and will be used for mutation analysis in testing BRCA2 candidate genes. Peripheral blood lymphocytes will be collected from living family members and paraffin-embedded tissue will be utilized as a source of DNA for linkage analysis from deceased family members. One affected family member will also undergo karyotyping in an attempt to identify balanced translocations or other visible chromosomal abnormalities which may involve the BRCA2 locus. Tumors from affected individuals in linked families will be studied for LOH in the BRCA2 candidate region as a means of further narrowing the candidate region. A physical map of the BRCA2 region is being constructed by our collaborators. The map already includes full coverage by yeast artificial chromosomes (YACs) and is approximately 50% covered with bacterial artificial chromosomes (BACs) and P1 clones. BAC and P1 genomic clones encompassed by the most tightly linked markers will be searched for potential transcripts by exon trapping and direct selection. Potential candidate cDNAs will be analyzed for the presence of germline mutations in affected individuals from BRCA2-linked families. The presence of germline mutations in families with evidence of linkage to BRCA2 will serve to identify a candidate gene as BRCA2. Once BRCA2 has been isolated (by us or others), we will expand our search for BRCA2 mutations to a bank of DNA collected from more than 300 women with a family history of breast cancer and/or a diagnosis of breast cancer before the age of 40. This panel of samples should be very useful in describing the spectrum of BRCA2 mutations in such a population, and these data will be added to an international study of genotype/phenotype correlation in families with inherited susceptibility to breast cancer as a result of germline mutations in BRCA1 or BRCA2. Perhaps of greatest significance however is that identification of BRCA2 will be pivotal in our understanding of the development of breast cancer, and will hasten the time when we can accurately define a cohort of women at very high risk of developing breast cancer and prevent the development of this devasting and potentially fatal disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057601-07
Application #
2837665
Study Section
Pathology B Study Section (PTHB)
Program Officer
Lively, Tracy (LUGO)
Project Start
1992-09-01
Project End
2000-11-30
Budget Start
1998-12-01
Budget End
2000-11-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Colilla, Susan; Kantoff, Philip W; Neuhausen, Susan L et al. (2006) The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 27:599-605
Gronwald, Jacek; Tung, Nadine; Foulkes, William D et al. (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118:2281-4
Rebbeck, Timothy R; Friebel, Tara; Lynch, Henry T et al. (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055-62
Grushko, Tatyana A; Dignam, James J; Das, Soma et al. (2004) MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10:499-507
Armstrong, Katrina; Weber, Barbara; FitzGerald, Genevieve et al. (2003) Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am J Med Genet A 120A:359-64
Armstrong, Katrina; Weiner, Janet; Weber, Barbara et al. (2003) Early adoption of BRCA1/2 testing: who and why. Genet Med 5:92-8
Armstrong, Katrina; Stopfer, Jill; Calzone, Kathleen et al. (2002) What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test 6:115-8
Armstrong, Katrina; Weber, Barbara; Ubel, Peter A et al. (2002) Interest in BRCA1/2 testing in a primary care population. Prev Med 34:590-5
Rebbeck, Timothy R; Lynch, Henry T; Neuhausen, Susan L et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-22
Grushko, Tatyana A; Blackwood, M Anne; Schumm, Phil L et al. (2002) Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62:1481-8

Showing the most recent 10 out of 45 publications